Latest Articles
Gender questions on healthcare benefits - Corporate Adviser
Gender questions on healthcare benefits Corporate Adviser
Published: Oct. 15, 2024, 3:48 p.m.
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer - OncLive
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer OncLive
Published: July 3, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets - The ASCO Post
Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets The ASCO Post
Published: June 10, 2024, 7 a.m.
NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency - Nature.com
NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency Nature.com
Published: May 30, 2024, 7 a.m.
Thousands of Aussies to benefit from new medicine listings on PBS - Sky News Australia
Thousands of Aussies to benefit from new medicine listings on PBS Sky News Australia
Published: May 13, 2024, 7 a.m.
Australians benefit from new lifechanging medicines added to the PBS - Department of Health
Australians benefit from new lifechanging medicines added to the PBS Department of Health
Published: May 13, 2024, 7 a.m.
Revealed: people with cancer, arthritis and amputations among 40% denied disability benefits - The Guardian
Revealed: people with cancer, arthritis and amputations among 40% denied disability benefits The Guardian
Published: May 12, 2024, 7 a.m.
Former Tetbury mayor Ann Pearce admits falsely claiming benefits - BBC.com
Former Tetbury mayor Ann Pearce admits falsely claiming benefits BBC.com
Published: April 29, 2024, 7 a.m.
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses - Nature.com
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses Nature.com
Published: April 23, 2024, 7 a.m.
Link copied to clipboard!